Is there a connection between mitoquinol (mitoquinol) use and the development of atrial fibrillation in adult patients, possibly with a history of neurodegenerative disease or mitochondrial dysfunction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 18, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

No Direct Connection Between Mitoquinol and Atrial Fibrillation

Based on the available evidence, there is no established connection between mitoquinol use and the development of atrial fibrillation. The provided guidelines and research literature do not mention mitoquinol as a causative agent for AF.

What the Evidence Shows About AF Causes

The comprehensive literature on AF etiology does not identify mitoquinol among recognized triggers or risk factors:

Established Drug-Induced AF

  • Cardiovascular, respiratory, cytostatic, and central nervous system drugs have been documented to induce AF, particularly in elderly patients on polypharmacy 1, 2
  • Drug-induced AF represents an increasingly recognized cause, especially with anticancer agents 1
  • However, mitoquinol is notably absent from systematic reviews of drug-induced AF 2

Mitochondrial Dysfunction and AF: A Theoretical Link

While mitoquinol is a mitochondrial-targeted antioxidant, the relationship between mitochondrial dysfunction and AF works in the opposite direction than your question implies:

  • Mitochondrial dysfunction is a consequence and driver of AF progression, not typically caused by mitochondrial-protective agents 3, 4, 5
  • AF causes progressive mitochondrial dysfunction through energy depletion, impaired oxidative phosphorylation, increased reactive oxygen species, and mtDNA damage 4, 5
  • Atrial tissue from AF patients demonstrates significant ATP deficit (5.4±1.2 nmol/mg in AF with heart failure vs 17±3.8 nmol/mg without heart failure) 4
  • Accumulation of mtDNA deletion mutations correlates with both aging and AF presence 6

Therapeutic Implications

  • Compounds that improve mitochondrial bioenergetics, like SS31, actually protect against AF-related cardiomyocyte remodeling 5
  • Preventing increased mitochondrial calcium influx attenuates AF remodeling 5
  • This suggests mitochondrial-protective agents would theoretically reduce, not increase, AF risk

Clinical Context

If a patient on mitoquinol develops AF, look for established risk factors rather than attributing causation to the medication 7, 1:

  • Hypertension with left ventricular hypertrophy 1
  • Heart failure (3-year AF incidence approaches 10%) 1
  • Valvular disease, particularly mitral valve disease 1
  • Cardiomyopathies (hypertrophic, dilated, restrictive) 8, 1
  • Hyperthyroidism (causes AF in 10-25% of patients) 7
  • Coronary artery disease 1
  • Age-related atrial fibrosis (0.5-1.0% cardiomyocyte replacement per year) 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.